| Prev Close | 16.96 |
| Open | 16.96 |
| Day Low/High | 16.96 / 16.98 |
| 52 Wk Low/High | 3.02 / 17.05 |
| Volume | 8.44M |
| Avg Volume | 6.29M |
| Exchange | NASDAQ |
| Shares Outstanding | 193.76M |
| Market Cap | 3.29B |
| EPS | -0.31 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
NUEDEXTA® Effective For Pseudobulbar Affect (PBA) In Patients With Alzheimer's Disease And Other Dementias, Stroke And Traumatic Brain Injury
-- PRISM II study published in BMC Neurology adds to clinical evidence demonstrating NUEDEXTA efficacy for PBA across diverse neurological disorders --
Avanir Pharmaceuticals Announces FDA Approval Of ONZETRA™ Xsail™ (AVP-825) For The Acute Treatment Of Migraine In Adults
--ONZETRA Xsail is the first breath-powered intranasal medication delivery system for the acute treatment of migraine--
Avanir Pharmaceuticals Announces Publication Of Study Evaluating The Prevalence Of Pseudobulbar Affect (PBA) Symptoms And Use Of Antipsychotic Medications In Nursing Homes
-- First Study to Evaluate the Prevalence of PBA Symptoms in Nursing Home Residents Found Almost 1 in 10 Residents Had Symptoms of PBA; These Patients with PBA Symptoms were Twice as Likely to Receive Antipsychotics --
Avanir Pharmaceuticals Announces Initiation Of Phase III Trial Of AVP-786 For Agitation In Patients With Alzheimer's Disease
-- AVP-786 Granted FDA Fast Track Designation for This Indication --
Avanir Pharmaceuticals Announces New Findings From Dementia/Alzheimer's Disease Cohort Of PRISM II Study At Alzheimer's Association International Conference
--New Data Demonstrate Treatment Effects on Pseudobulbar Affect (PBA) with NUEDEXTA Regardless of Concomitant Antidepressant Use--
Avanir Pharmaceuticals Announces Positive Top-line Results From Stroke And TBI Cohorts Of PRISM II Study
-- Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in PBA Patients Who Had an Underlying Stroke or Traumatic Brain Injury --
Avanir Pharmaceuticals Announces Presentation Of Survey Evaluating The Prevalence Of Pseudobulbar Affect (PBA) Symptoms In Retired Professional Football Players At The 12th Annual North American Brain Injury Society Conference
-- Ninety nine percent of respondents experienced some form of brain trauma during their playing career and one third also report symptoms of PBA --
Danny Glover Joins PBA Facts Campaign, To Educate And Build Awareness Of Pseudobulbar Affect (PBA), A Little Known But Widespread Neurologic Condition
--Avanir Pharmaceuticals Takes Unique Approach to Patient Education in New Initiative--
Football Hall-of-Famer Barry Sanders Tackles Pseudobulbar Affect; A Little-known But Widespread Condition Caused By Brain Injury
'Tackle PBA,' a New Educational Campaign, Addresses Why Many Former Pro Football Players Cry or Laugh Uncontrollably with Little to No Clear Trigger
Updating a Small Speculative Play
Synergy Pharmaceuticals is developing drugs to treat gastrointestinal disorders and diseases. The
Through Laughter And Tears Comes First-Ever Documentary About Life With PseudoBulbar Affect (PBA)
--Award-Winning Filmmakers Capture Untold Story of Little-Known Neurologic Condition That Affects Nearly 2 Million Americans--
